AMAM News and Press, Ambrx Biopharma Inc. American Depositary Shares (each representing seven) From 09/15/23

2023-09-15 13:11:06 ET Gainers: MSP Recovery ( LIFW ) +199% . AERWINS Technologies ( AWIN ) +104% . AgriFORCE Growing Systems Ltd. ( AGRI ) +40% . RayzeBio ( RYZB ) +37% . Novonix Limited ( NVX ) +31% . Greenland Technologies...

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview and participate in one-on-one meetings at th...

2023-09-01 17:32:58 ET Gainers: Diversified Healthcare  ( DHC ) +10% . Airbnb ( ABNB ) +5% . Ambrx Biopharma  ( AMAM ) +5% . NAPCO Security Technologies ( NSSC ) +5% . Premier ( PINC ) +5% . Losers: The Growth f...

2023-08-21 12:30:54 ET Summary Ambrx Biopharma is a clinical-stage biotech company developing precision biologics for cancer treatment. They have a strong financial position with $235.1 million in liquid assets and a cash runway of approximately four years. Their leading candi...

SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company’...

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the acceptance of four abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in M...

2023-07-19 09:27:17 ET Shares of Ambrx Biopharma ( NASDAQ: AMAM ) gained after the drug developer said that the FDA issued its Fast Track designation for the company's experimental antibody drug conjugate ARX517 for the treatment of patients with prostate cancer as a late-line optio...

SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx’s proprietary anti-PSMA antibody-drug conjugate (ADC) inves...

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the closing of its previously announced market-priced registered direct offering of approximately $75 million (the “Offering”) of its American...

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the TD Cowen Oncology Innovation Summit,...